Cargando…

Neuroprotective Effect of Trans-Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial

INTRODUCTION: Amyloid-beta (Aβ) protein is a major component of the extracellular plaque found in the brains of individuals with Alzheimer's disease (AD). In this study, we investigated the effect of trans-resveratrol as an antagonist treatment for moderate to mild AD, as well as its safety and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Jiachen, Li, Zongshan, Chen, Huimin, Xu, Xiaomin, Li, Yongang, Gui, Yaxing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571425/ https://www.ncbi.nlm.nih.gov/pubmed/34402024 http://dx.doi.org/10.1007/s40120-021-00271-2

Ejemplares similares

Cerebrospinal Fluid Extracellular Vesicles with Distinct Properties in Autoimmune Encephalitis and Herpes Simplex Encephalitis
por: Li, Yongang, et al.
Publicado: (2022)

trans-Resveratrol as A Neuroprotectant
por: Robb, Ellen L., et al.
Publicado: (2010)

Recent Advances on Extracellular Vesicles in Central Nervous System Diseases
por: Jin, Tao, et al.
Publicado: (2021)

Neuroprotective effects of resveratrol in Alzheimer disease pathology
por: Rege, Shraddha D., et al.
Publicado: (2014)

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
por: Turner, R. Scott, et al.
Publicado: (2015)

Neuroprotective Mechanisms of Resveratrol in Alzheimer's Disease: Role of SIRT1
por: Gomes, Bruno Alexandre Quadros, et al.
Publicado: (2018)

Resveratrol and Neuroprotection: Impact and Its Therapeutic Potential in Alzheimer's Disease
por: Rahman, Md. Habibur, et al.
Publicado: (2020)

NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease
por: Lawlor, Brian, et al.
Publicado: (2014)

Effect of PLA2G6 and SMPD1 Variants on the Lipid Metabolism in the Cerebrospinal Fluid of Patients with Parkinson's Disease: A Non-targeted Lipidomics Study
por: Li, Yongang, et al.
Publicado: (2023)

Neuroprotective Effects of Cistanches Herba Therapy on Patients with Moderate Alzheimer's Disease
por: Li, Nan, et al.
Publicado: (2015)

Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)
por: Aisen, Paul S., et al.
Publicado: (2011)

Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial
por: Henderson, Samuel T, et al.
Publicado: (2009)

First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease
por: Ferrero, James, et al.
Publicado: (2016)

ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension
por: Gault, Laura M., et al.
Publicado: (2016)

Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial
por: Dubée, Vincent, et al.
Publicado: (2021)

Randomized Double-blind Placebo-controlled Proof-of-concept Trial of Resveratrol for Outpatient Treatment of Mild Coronavirus Disease (COVID-19)
por: McCreary, Marvin R., et al.
Publicado: (2021)

Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19)
por: McCreary, Marvin R., et al.
Publicado: (2022)

Study of the Neuroprotective Effects of Memantine in Patients with Mild to Moderate Ischemic Stroke
por: Kafi, Hamidreza, et al.
Publicado: (2014)

Neuroprotective Effect of S-trans, Trans-farnesylthiosalicylic Acid via Inhibition of RAS/ERK Pathway for the Treatment of Alzheimer’s Disease
por: Wang, Xiang, et al.
Publicado: (2019)

Effects of probiotic supplements on cognition, anxiety, and physical activity in subjects with mild and moderate Alzheimer’s disease: A randomized, double-blind, and placebo-controlled study
por: Akhgarjand, Camellia, et al.
Publicado: (2022)

Biotransformation of Resveratrol: New Prenylated trans-Resveratrol Synthesized by Aspergillus sp. SCSIOW2
por: Wang, Liyan, et al.
Publicado: (2016)

The Neuroprotective Effects of Moderate and Regular Caffeine Consumption in Alzheimer's Disease
por: Zhou, Xiangyu, et al.
Publicado: (2021)

Neuroprotective Properties of Resveratrol and Its Derivatives—Influence on Potential Mechanisms Leading to the Development of Alzheimer’s Disease
por: Wiciński, Michał, et al.
Publicado: (2020)

Characteristics of falls in mild and moderate Alzheimer’s disease
por: Kato-Narita, Eliane Mayumi, et al.
Publicado: (2009)

Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial
por: Bloch, Yehudit, et al.
Publicado: (2021)

A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia
por: Xiao, Shifu, et al.
Publicado: (2021)

A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms
por: Bernard, Katy, et al.
Publicado: (2019)

Addition of Trans-Resveratrol-Loaded Highly Concentrated Double Emulsion to Yoghurts: Effect on Physicochemical Properties
por: Díaz-Ruiz, Rocío, et al.
Publicado: (2021)

Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease
por: Cummings, Jeffrey L., et al.
Publicado: (2016)

Effects of Lianhuaqingwen Capsules in adults with mild-to-moderate coronavirus disease 2019: an international, multicenter, double-blind, randomized controlled trial
por: Zheng, Jin-ping, et al.
Publicado: (2023)

Electrochemical Evaluation of trans-Resveratrol Levels in Red Wine Based on the Interaction between Resveratrol and Graphene
por: Liu, Lantao, et al.
Publicado: (2017)

Antioxidant and neuroprotective actions of resveratrol in cerebrovascular diseases
por: Wang, Qing, et al.
Publicado: (2022)

Leishmanicidal Effect of Synthetic trans-Resveratrol Analogs
por: Passos, Carlos Luan Alves, et al.
Publicado: (2015)

Topical nicotinamide in combination with calcipotriol for the treatment of mild to moderate psoriasis: A double-blind, randomized, comparative study
por: Siadat, Amir Hossein, et al.
Publicado: (2013)

Amelioration of mild and moderate depression through Pranic Healing as adjuvant therapy: randomised double-blind controlled trial
por: Rajagopal, R, et al.
Publicado: (2017)

A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19
por: Rossignol, Jean-François, et al.
Publicado: (2022)

Trans ε-Viniferin Decreases Amyloid Deposits With Greater Efficiency Than Resveratrol in an Alzheimer’s Mouse Model
por: Freyssin, Aline, et al.
Publicado: (2022)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
por: Seltzer, Ben
Publicado: (2010)

Neuropsychological Rehabilitation in Mild and Moderate Alzheimer’s Disease Patients
por: Ávila, Renata, et al.
Publicado: (2007)

The conceptual relevance of assessment measures in patients with mild/mild-moderate Alzheimer's disease
por: Hartry, Ann, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_b8ua3poaqhtf1quvv4nrsd54k6